Abivertinib

马来酸艾维替尼

Report date: 2024/06/04 16:19:28
NME

Base Information

Drug NameAbivertinib
Drug Alias NameAvitinib MaleateA-610MAAC-0010AC-0100AC-001 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsEGFR T790M inhibitors
TargetsTyrosine-protein kinase BTKEGFR T790M
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Prostatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceBrazil +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZhejiang Acea Pharmaceutical Co LtdHangzhou Acea Pharmaceutical Research Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSorrento Therapeutics IncHangzhou Acea Pharmaceutical Research Co LtdAgilent Biosciences (Hangzhou) Co Ltd
Inactive CompaniesAcea Therapeutics IncSun Yat-Sen UniversityZhejiang Acea Pharmaceutical Co Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)Carcinoma, Non-Small-Cell LungLymphoma, Mantle-Cell +[7] 
Inactive IndicationsProstatic NeoplasmsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A